Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Genitourinary tumours, prostate

2871 - What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis


10 Sep 2017


Genitourinary tumours, prostate


Cytotoxic Therapy;  Prostate Cancer


Claire Vale


Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440


C.L. Vale1, D.J. Fisher1, J. Carpenter1, I.R. White1, S. Burdett1, N.W. Clarke2, K. Fizazi3, G. Gravis4, N.D. James5, M.D. Mason6, M.K. Parmar1, L.H. Rydzewska1, C.J. Sweeney7, M.R. Spears1, M.R. Sydes1, J.F. Tierney1

Author affiliations

  • 1 Mrc Clinical Trials Unit At Ucl, Institute of Clinical Trials and Methodology, WC2B 6NH - London/GB
  • 2 Dept Of Oncology, Royal Salford NHS Foundation Trust, M6 8HD - Salford/GB
  • 3 Dept Of Cancer Medicine, Gustave Roussy, 94800 - Villejuif/FR
  • 4 Dept Of Medical Oncology, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 5 Clinical Trials Unit, The Institute of Cancer and Genomic Sciences, B15 2TT - Birmingham/GB
  • 6 School Of Medicine, Cardiff University, Cardiff - Cardiff/GB
  • 7 Lank Center For Genitourinary Oncology, Dana-Farber Cancer Institute, Boston/US


Abstract 2871


Our prior STOPCaP systematic reviews showed improved survival for men with metastatic hormone-sensitive prostate cancer (mHSPC) when abiraterone acetate plus prednisolone/prednisone (AAP) or docetaxel (DOC), but not zoledronic acid (ZA), were added to androgen deprivation therapy (ADT). Trial evidence also suggests a benefit of combining celecoxib (CEL) with ZA and ADT. To establish the optimal treatments, a network meta-analysis (NMA) was performed based on aggregate data (AD) from all available studies.


Overall survival (OS) data from completed reviews of DOC, ZA and AAP and from recent trials of ZA and CEL contribute to this new comprehensive AD-NMA. Correlations between treatment comparisons within multi-arm multi-stage (MAMS) trials (e.g. STAMPEDE) were estimated from control-arm event counts in overlapping recruitment periods. We assumed network consistency and a common heterogeneity variance.


Network estimates of effects on OS were consistent with reported comparisons with ADT alone for: AAP (HR = 0.61, 95% CI 0.51-0.76); DOC (HR = 0.74, 95% CI 0.65-0.85); CEL+ZA (HR = 0.77 95%CI 0.62-0.96) and DOC+ZA (HR = 0.78 95% CI 0.65-0.93). The effect of CEL+ZA is consistent with the additive effects of the individual treatments. Based on the current data, the network OS results suggest that AAP has the highest probability of being best, and DOC second-best. ADT, ZA and CEL have the highest probability of being worst. Results for failure-free survival will be presented.


Uniquely, we have included all available results and appropriately accounted for inclusion of MAMS trials in this AD-NMA. Our results clearly support the use of AAP or DOC with ADT in men with mHSPC; direct evidence from the STAMPEDE trial (Abstract #3632) and the ongoing PEACE-1 trial (NCT01957436) will corroborate (or otherwise) their relative effects. A NMA based on individual participant data is in development to fully account for patient variability across trials, changes in prognosis or treatment effects over time, and the potential impact of treatment on progression.

Clinical trial identification


Legal entity responsible for the study

University College London


UK Medical Research Council


J. Carpenter: Funded by the MRC, HEFCE and contributions from NIHR, ESRC, MRC and EU funds. He undertakes methodological consultancy work for Novartis and GlaxoSmithKline, and has given courses for GlaxoSmithKline, Bayer and Boehringer. N.W. Clarke: Advisory Boards: Astellas, Janssen, Ferring, Bayer, AstraZeneca; Corporate-sponsored Research: AstraZeneca. K. Fizazi: Advisory boards for Sanofi and Novartis. G. Gravis: Travel grants from Sanofi, Astellas and Janssen. N.D. James: Grants, personal fees and non-financial support from Janssen, Astellas, Sanofi, Novartis during the conduct of the study; grants and non-financial support from Clovis Oncology, Pfizer M.D. Mason: Delivering a paid lecture for Janssen and has been an advisory board member for Sanofi and Bayer. M.K. Parmar: Grants from Astellas, Janssen, Novartis, Pfizer, Sanofi and Clovis Oncology C.J. Sweeney: Ownership BIND; Advisory board Astellas/Medivation, Astra Zeneca, Sanofi, Janssen, BIND, Bayer; Grants Janssen, Astellas/Medivation, Sanofi, Janssen, Soti, Exelixis; Consultancy Astellas/Medivation, Pfizer, Sanofi, Janssen, BIND, Bayer, Genentech. M.R. Spears, M.R. Sydes: Grants from Astellas, Janssen, Novartis, Pfizer, Sanofi and Clovis Oncology. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.